Publications by authors named "J M Newcomb"
Gout flares after stopping anti-inflammatory prophylaxis: a rapid literature review and meta-analysis.
Arthritis Care Res (Hoboken)
December 2024
Objective: The aim of this research was to determine how common gout flares are after ceasing anti-inflammatory prophylaxis.
Methods: A rapid literature review and meta-analysis were undertaken. PubMed was searched from inception to February 2024.
Despite significant progress in the treatment of multiple myeloma (MM), relapsed/refractory patients urgently require more effective therapies. We here describe the discovery, mechanism of action, and preclinical anti-MM activity of engineered toxin body MT-0169, a next-generation immunotoxin comprising a CD38-specific antibody fragment linked to a de-immunized Shiga-like toxin A subunit (SLTA) payload. We show that specific binding of MT-0169 to CD38 on MM cell lines triggers rapid internalization of SLTA, causing cell death via irreversible ribosome inhibition, protein synthesis blockade, and caspase 3/7 activation.
View Article and Find Full Text PDFBackground And Objectives: Noradrenergic dysregulation is important in the pathophysiology of posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD); pharmacotherapies targeting adrenergic function have potential as treatment for comorbidity. Dexmedetomidine (sublingual film formulation-BXCL501; IGALMI) is a highly potent, selective ⍺2-adrenergic receptor agonist and may be superior to other pharmacotherapeutic approaches. A within subjects, phase 1b safety laboratory study was conducted to evaluate adverse effects of BXCL501 when combined with alcohol; BXCL501's potential efficacy was also explored.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the risk of arthritis flares when starting urate-lowering therapy (ULT) with allopurinol versus febuxostat in gout patients, focusing on the first 24 weeks of treatment.
- It analyzed data from a trial involving 940 male participants, examining flare occurrences and various predictors such as treatment type and serum urate levels.
- The findings indicated that the risk of gout flares was similar for both medications when using effective treatment strategies, with notable predictors of flare being younger age, higher initial urate levels, and the absence of tophi.
Rationale & Objective: We conducted a prespecified examination of the efficacy and safety of allopurinol and febuxostat administered using a treat-to-target strategy in trial participants with chronic kidney disease (CKD).
Study Design: Prespecified subcohort analysis of a randomized controlled trial.
Setting & Participants: A substudy of the STOP Gout Trial in participants with CKD.